Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Miravo Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
Brand Name : Blexten
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2022
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Miravo Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
